Disease · MONDO_0002817

adrenal gland cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adrenal gland cancer. Diseases, record MONDO_0002817. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002817

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adrenal gland cancer; Open Targets
Open Targets ID: MONDO_0002817; Open Targets
Other names: adrenal cancer, cancer of adrenal gland, malignant adrenal gland neoplasm, malignant adrenal gland tumor, malignant adrenal gland tumour, malignant adrenal neoplasm, malignant adrenal tumor, malignant adrenal tumour, malignant neoplasm of adrenal gland, malignant neoplasm of the adrenal gland, malignant tumor of adrenal gland, malignant tumor of the adrenal gland, malignant tumour of adrenal gland, malignant tumour of the adrenal gland; Open Targets
Disease Ontology: DOID:3953; Disease Ontology
MeSH: D000310; MeSH
NCI Thesaurus: C9338; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 6 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ANTINEOPLASTON A10	CHEMBL1980825	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TAMOXIFEN CITRATE	CHEMBL786	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
SORAFENIB	CHEMBL1336	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets51

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRM1	26S proteasome	1	26S proteasome inhibitor	Phase 1	https://conductscience.org/library/genes/11047	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	1	Serine/threonine-protein kinase B-raf inhibitor	Phase 1	https://conductscience.org/library/genes/673	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor alpha modulator	Phase 2	https://conductscience.org/library/genes/2099	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/2321	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	1	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 1	https://conductscience.org/library/genes/2322	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	1	Platelet-derived growth factor receptor beta inhibitor	Phase 1	https://conductscience.org/library/genes/5159	Drugs and targets

1 to 10 of 51

See all 51 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00001880	Stem Cell Transplantation for Metastatic Solid Tumors	Phase 2	42	2021-11-10	Neoplasm Metastasis	CYCLOSPORINE, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT00003453	Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer	Phase 2	6	2018-05-09	Stage IV Adrenocortical Carcinoma	ANTINEOPLASTON A10	Its record names the disease	ClinicalTrials.gov
NCT00002608	Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	Phase 2	30		Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer, Malignant Mesothelioma, Pheochromocytoma, Sarcoma	CISPLATIN, DOXORUBICIN HYDROCHLORIDE, TAMOXIFEN CITRATE	Its record names the disease	ClinicalTrials.gov
NCT00303797	Sorafenib and Bortezomib in Treating Patients With Advanced Cancer	Phase 1	14		Adult Solid Neoplasm, DS Stage III Multiple Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia	BORTEZOMIB, SORAFENIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
23887852	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002817

GET https://conductscience.org/api/diseases/v1/MONDO_0002817/targets?page=2

API reference For AI assistants